ID   NFL_HUMAN               Reviewed;         543 AA.
AC   P07196; B9ZVN2; Q16154; Q8IU72;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   28-JUN-2023, entry version 235.
DE   RecName: Full=Neurofilament light polypeptide;
DE            Short=NF-L;
DE   AltName: Full=68 kDa neurofilament protein;
DE   AltName: Full=Neurofilament triplet L protein;
GN   Name=NEFL; Synonyms=NF68, NFL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3034332; DOI=10.1016/0167-4781(87)90041-8;
RA   Julien J.-P., Grosveld F., Yazdanbaksh K., Flavell D., Meijer D.,
RA   Mushynski W.;
RT   "The structure of a human neurofilament gene (NF-L): a unique exon-intron
RT   organization in the intermediate filament gene family.";
RL   Biochim. Biophys. Acta 909:10-20(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=12432080; DOI=10.1242/jcs.00148;
RA   Perez-Olle R., Leung C.L., Liem R.K.;
RT   "Effects of Charcot-Marie-Tooth-linked mutations of the neurofilament light
RT   subunit on intermediate filament formation.";
RL   J. Cell Sci. 115:4937-4946(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-11.
RX   PubMed=8180132;
RA   Pospelov V.A., Pospelova T.V., Julien J.-P.;
RT   "AP-1 and Krox-24 transcription factors activate the neurofilament light
RT   gene promoter in P19 embryonal carcinoma cells.";
RL   Cell Growth Differ. 5:187-196(1994).
RN   [7]
RP   PROTEIN SEQUENCE OF 38-54; 213-224; 340-353; 380-390 AND 422-437, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Fetal brain cortex;
RA   Lubec G., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [8]
RP   PROTEIN SEQUENCE OF 468-473.
RC   TISSUE=Brain;
RX   PubMed=6135695; DOI=10.1093/jb/93.3.825;
RA   Nomata Y., Watanabe T., Wada H.;
RT   "Highly acidic proteins from human brain: purification and properties of
RT   Glu-50 protein.";
RL   J. Biochem. 93:825-831(1983).
RN   [9]
RP   PHOSPHORYLATION BY PKN1.
RX   PubMed=8621664; DOI=10.1074/jbc.271.16.9816;
RA   Mukai H., Toshimori M., Shibata H., Kitagawa M., Shimakawa M., Miyahara M.,
RA   Sunakawa H., Ono Y.;
RT   "PKN associates and phosphorylates the head-rod domain of neurofilament
RT   protein.";
RL   J. Biol. Chem. 271:9816-9822(1996).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [12]
RP   VARIANT CMT2E PRO-332.
RX   PubMed=10841809; DOI=10.1086/302962;
RA   Mersiyanova I.V., Perepelov A.V., Polyakov A.V., Sitnikov V.F.,
RA   Dadali E.L., Oparin R.B., Petrin A.N., Evgrafov O.V.;
RT   "A new variant of Charcot-Marie-Tooth disease type 2 is probably the result
RT   of a mutation in the neurofilament-light gene.";
RL   Am. J. Hum. Genet. 67:37-46(2000).
RN   [13]
RP   VARIANT CMT2E ARG-8.
RX   PubMed=11220745;
RX   DOI=10.1002/1531-8249(20010201)49:2<245::aid-ana45>3.0.co;2-a;
RA   De Jonghe P., Mersivanova I., Nelis E., Del Favero J., Martin J.-J.,
RA   Van Broeckhoven C., Evgrafov O., Timmerman V.;
RT   "Further evidence that neurofilament light chain gene mutations can cause
RT   Charcot-Marie-Tooth disease type 2E.";
RL   Ann. Neurol. 49:245-249(2001).
RN   [14]
RP   VARIANT CMT2E SER-22.
RX   PubMed=12481988; DOI=10.1007/s10048-002-0138-4;
RA   Georgiou D.-M., Zidar J., Korosec M., Middleton L.T., Kyriakides T.,
RA   Christodoulou K.;
RT   "A novel NF-L mutation Pro22Ser is associated with CMT2 in a large
RT   Slovenian family.";
RL   Neurogenetics 4:93-96(2002).
RN   [15]
RP   VARIANTS CMT1F ARG-8; LEU-8; GLN-8; LYS-90; SER-98 AND GLU-527 DEL, AND
RP   VARIANTS LYS-7 AND ASN-468.
RX   PubMed=12566280; DOI=10.1093/brain/awg059;
RA   Jordanova A., De Jonghe P., Boerkoel C.F., Takashima H., De Vriendt E.,
RA   Ceuterick C., Martin J.-J., Butler I.J., Mancias P., Papasozomenos S.C.,
RA   Terespolsky D., Potocki L., Brown C.W., Shy M., Rita D.A., Tournev I.,
RA   Kremensky I., Lupski J.R., Timmerman V.;
RT   "Mutations in the neurofilament light chain gene (NEFL) cause early onset
RT   severe Charcot-Marie-Tooth disease.";
RL   Brain 126:590-597(2003).
RN   [16]
RP   VARIANT CMT2E PRO-336, AND VARIANT CMT1F LYS-396.
RX   PubMed=15241803; DOI=10.1002/humu.9261;
RA   Choi B.-O., Lee M.S., Shin S.H., Hwang J.H., Choi K.-G., Kim W.-K.,
RA   Sunwoo I.N., Kim N.K., Chung K.W.;
RT   "Mutational analysis of PMP22, MPZ, GJB1, EGR2 and NEFL in Korean Charcot-
RT   Marie-Tooth neuropathy patients.";
RL   Hum. Mutat. 24:185-186(2004).
RN   [17]
RP   VARIANT CMTDIG LYS-396.
RX   PubMed=14733962; DOI=10.1016/j.nmd.2003.10.003;
RA   Zuechner S., Vorgerd M., Sindern E., Schroeder J.M.;
RT   "The novel neurofilament light (NEFL) mutation Glu397Lys is associated with
RT   a clinically and morphologically heterogeneous type of Charcot-Marie-Tooth
RT   neuropathy.";
RL   Neuromuscul. Disord. 14:147-157(2004).
RN   [18]
RP   VARIANTS MET-213 AND ASN-468, VARIANTS CMT2E SER-22; PRO-268 AND
RP   322-CYS--ASN-326 DEL, AND VARIANT CMTDIG LYS-396.
RX   PubMed=17052987; DOI=10.1093/brain/awl284;
RA   Fabrizi G.M., Cavallaro T., Angiari C., Cabrini I., Taioli F., Malerba G.,
RA   Bertolasi L., Rizzuto N.;
RT   "Charcot-Marie-Tooth disease type 2E, a disorder of the cytoskeleton.";
RL   Brain 130:394-403(2007).
RN   [19]
RP   VARIANTS CMT2E ARG-8; SER-22 AND LYS-396.
RX   PubMed=22206013; DOI=10.1371/journal.pone.0029393;
RA   Lin K.P., Soong B.W., Yang C.C., Huang L.W., Chang M.H., Lee I.H.,
RA   Antonellis A., Lee Y.C.;
RT   "The mutational spectrum in a cohort of Charcot-Marie-Tooth disease type 2
RT   among the Han Chinese in Taiwan.";
RL   PLoS ONE 6:E29393-E29393(2011).
RN   [20]
RP   VARIANT CMTDIG LYS-396, AND INVOLVEMENT IN CMTDIG.
RX   PubMed=25877835; DOI=10.1007/s00415-015-7709-4;
RA   Berciano J., Garcia A., Peeters K., Gallardo E., De Vriendt E.,
RA   Pelayo-Negro A.L., Infante J., Jordanova A.;
RT   "NEFL E396K mutation is associated with a novel dominant intermediate
RT   Charcot-Marie-Tooth disease phenotype.";
RL   J. Neurol. 262:1289-1300(2015).
RN   [21]
RP   VARIANTS CMT2E CYS-265; PRO-268; PRO-336 AND LEU-440.
RX   PubMed=25802885; DOI=10.1002/mgg3.126;
RA   Drew A.P., Zhu D., Kidambi A., Ly C., Tey S., Brewer M.H., Ahmad-Annuar A.,
RA   Nicholson G.A., Kennerson M.L.;
RT   "Improved inherited peripheral neuropathy genetic diagnosis by whole-exome
RT   sequencing.";
RL   Mol. Genet. Genomic Med. 3:143-154(2015).
RN   [22]
RP   VARIANT CMTDIG SER-98, AND INVOLVEMENT IN CMTDIG.
RX   PubMed=26645395; DOI=10.1007/s00415-015-7985-z;
RA   Berciano J., Peeters K., Garcia A., Lopez-Alburquerque T., Gallardo E.,
RA   Hernandez-Fabian A., Pelayo-Negro A.L., De Vriendt E., Infante J.,
RA   Jordanova A.;
RT   "NEFL N98S mutation: another cause of dominant intermediate Charcot-Marie-
RT   Tooth disease with heterogeneous early-onset phenotype.";
RL   J. Neurol. 263:361-369(2016).
CC   -!- FUNCTION: Neurofilaments usually contain three intermediate filament
CC       proteins: NEFL, NEFM, and NEFH which are involved in the maintenance of
CC       neuronal caliber. May additionally cooperate with the neuronal
CC       intermediate filament proteins PRPH and INA to form neuronal
CC       filamentous networks (By similarity). {ECO:0000250|UniProtKB:P08551}.
CC   -!- SUBUNIT: Forms homodimers (in vitro) (By similarity). Forms
CC       heterodimers with NEFH or NEFM; which can further hetero-oligomerize
CC       (in vitro) (By similarity). Forms heterodimers with INA (in vitro) (By
CC       similarity). Interacts with ARHGEF28. Interacts with TRIM2.
CC       {ECO:0000250, ECO:0000250|UniProtKB:P19527}.
CC   -!- INTERACTION:
CC       P07196; P20933: AGA; NbExp=3; IntAct=EBI-475646, EBI-1223922;
CC       P07196; P13928: ANXA8; NbExp=3; IntAct=EBI-475646, EBI-2556915;
CC       P07196; Q9NP61: ARFGAP3; NbExp=3; IntAct=EBI-475646, EBI-2875816;
CC       P07196; Q9Y575-3: ASB3; NbExp=3; IntAct=EBI-475646, EBI-14199987;
CC       P07196; P21281: ATP6V1B2; NbExp=3; IntAct=EBI-475646, EBI-4290814;
CC       P07196; O95817: BAG3; NbExp=3; IntAct=EBI-475646, EBI-747185;
CC       P07196; Q8IXM2: BAP18; NbExp=3; IntAct=EBI-475646, EBI-4280811;
CC       P07196; Q8N865: C7orf31; NbExp=3; IntAct=EBI-475646, EBI-10174456;
CC       P07196; Q96LL4: C8orf48; NbExp=3; IntAct=EBI-475646, EBI-751596;
CC       P07196; Q8N5S9-2: CAMKK1; NbExp=3; IntAct=EBI-475646, EBI-25850646;
CC       P07196; Q8IYE1: CCDC13; NbExp=3; IntAct=EBI-475646, EBI-10961312;
CC       P07196; P0C7W6: CCDC172; NbExp=3; IntAct=EBI-475646, EBI-2548868;
CC       P07196; A0A1B0GWI1: CCDC196; NbExp=3; IntAct=EBI-475646, EBI-10181422;
CC       P07196; Q6P2R3: CEP57L1; NbExp=3; IntAct=EBI-475646, EBI-12696312;
CC       P07196; Q494V2-2: CFAP100; NbExp=3; IntAct=EBI-475646, EBI-11953200;
CC       P07196; Q9Y240: CLEC11A; NbExp=3; IntAct=EBI-475646, EBI-3957044;
CC       P07196; Q8IUI8: CRLF3; NbExp=3; IntAct=EBI-475646, EBI-2872414;
CC       P07196; Q7L576: CYFIP1; NbExp=3; IntAct=EBI-475646, EBI-1048143;
CC       P07196; Q5TAQ9-2: DCAF8; NbExp=3; IntAct=EBI-475646, EBI-25842815;
CC       P07196; P17661: DES; NbExp=7; IntAct=EBI-475646, EBI-1055572;
CC       P07196; P63172: DYNLT1; NbExp=3; IntAct=EBI-475646, EBI-1176455;
CC       P07196; Q6UXG2-3: ELAPOR1; NbExp=3; IntAct=EBI-475646, EBI-12920100;
CC       P07196; Q9H6S3: EPS8L2; NbExp=3; IntAct=EBI-475646, EBI-3940939;
CC       P07196; Q99504: EYA3; NbExp=3; IntAct=EBI-475646, EBI-9089567;
CC       P07196; Q6P587-2: FAHD1; NbExp=3; IntAct=EBI-475646, EBI-12902289;
CC       P07196; Q8IZU1: FAM9A; NbExp=3; IntAct=EBI-475646, EBI-8468186;
CC       P07196; Q8TC84: FANK1; NbExp=3; IntAct=EBI-475646, EBI-21975404;
CC       P07196; Q53R41: FASTKD1; NbExp=3; IntAct=EBI-475646, EBI-3957005;
CC       P07196; Q7L622: G2E3; NbExp=3; IntAct=EBI-475646, EBI-751757;
CC       P07196; P14136: GFAP; NbExp=9; IntAct=EBI-475646, EBI-744302;
CC       P07196; Q9NXC2: GFOD1; NbExp=3; IntAct=EBI-475646, EBI-8799578;
CC       P07196; Q08379: GOLGA2; NbExp=3; IntAct=EBI-475646, EBI-618309;
CC       P07196; Q9BQQ3: GORASP1; NbExp=3; IntAct=EBI-475646, EBI-2561458;
CC       P07196; A0A024R8L2: hCG_1987119; NbExp=3; IntAct=EBI-475646, EBI-14103818;
CC       P07196; Q14005-2: IL16; NbExp=3; IntAct=EBI-475646, EBI-17178971;
CC       P07196; Q6ZU52: KIAA0408; NbExp=3; IntAct=EBI-475646, EBI-739493;
CC       P07196; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-475646, EBI-14069005;
CC       P07196; Q6P597-2: KLC3; NbExp=3; IntAct=EBI-475646, EBI-11033402;
CC       P07196; P13646: KRT13; NbExp=3; IntAct=EBI-475646, EBI-1223876;
CC       P07196; P19012: KRT15; NbExp=3; IntAct=EBI-475646, EBI-739566;
CC       P07196; P05783: KRT18; NbExp=3; IntAct=EBI-475646, EBI-297888;
CC       P07196; P08727: KRT19; NbExp=3; IntAct=EBI-475646, EBI-742756;
CC       P07196; Q14525: KRT33B; NbExp=3; IntAct=EBI-475646, EBI-1049638;
CC       P07196; Q8IUC2: KRTAP8-1; NbExp=3; IntAct=EBI-475646, EBI-10261141;
CC       P07196; Q14847-2: LASP1; NbExp=3; IntAct=EBI-475646, EBI-9088686;
CC       P07196; A2RU56: LOC401296; NbExp=3; IntAct=EBI-475646, EBI-9088215;
CC       P07196; Q9NS73-5: MBIP; NbExp=3; IntAct=EBI-475646, EBI-10182361;
CC       P07196; P51608: MECP2; NbExp=3; IntAct=EBI-475646, EBI-1189067;
CC       P07196; Q15049: MLC1; NbExp=3; IntAct=EBI-475646, EBI-8475277;
CC       P07196; Q8IXL7-2: MSRB3; NbExp=3; IntAct=EBI-475646, EBI-10699187;
CC       P07196; Q13614: MTMR2; NbExp=2; IntAct=EBI-475646, EBI-475631;
CC       P07196; Q99608: NDN; NbExp=4; IntAct=EBI-475646, EBI-718177;
CC       P07196; O76041: NEBL; NbExp=3; IntAct=EBI-475646, EBI-2880203;
CC       P07196; P07197: NEFM; NbExp=4; IntAct=EBI-475646, EBI-1105035;
CC       P07196; Q9HC98-4: NEK6; NbExp=3; IntAct=EBI-475646, EBI-11750983;
CC       P07196; Q9Y5B8: NME7; NbExp=3; IntAct=EBI-475646, EBI-744782;
CC       P07196; Q6X4W1-6: NSMF; NbExp=3; IntAct=EBI-475646, EBI-25842707;
CC       P07196; Q7Z417: NUFIP2; NbExp=3; IntAct=EBI-475646, EBI-1210753;
CC       P07196; O43482: OIP5; NbExp=3; IntAct=EBI-475646, EBI-536879;
CC       P07196; Q9P286: PAK5; NbExp=3; IntAct=EBI-475646, EBI-741896;
CC       P07196; Q9BRX2: PELO; NbExp=3; IntAct=EBI-475646, EBI-1043580;
CC       P07196; Q96LB9: PGLYRP3; NbExp=3; IntAct=EBI-475646, EBI-12339509;
CC       P07196; Q16512: PKN1; NbExp=3; IntAct=EBI-475646, EBI-602382;
CC       P07196; Q6NYC8: PPP1R18; NbExp=3; IntAct=EBI-475646, EBI-2557469;
CC       P07196; Q8NI37: PPTC7; NbExp=3; IntAct=EBI-475646, EBI-9089276;
CC       P07196; Q9Y5P3: RAI2; NbExp=3; IntAct=EBI-475646, EBI-746228;
CC       P07196; Q96PK6: RBM14; NbExp=3; IntAct=EBI-475646, EBI-954272;
CC       P07196; Q9P2K3-2: RCOR3; NbExp=3; IntAct=EBI-475646, EBI-1504830;
CC       P07196; Q8TCX5: RHPN1; NbExp=3; IntAct=EBI-475646, EBI-746325;
CC       P07196; Q8N488: RYBP; NbExp=3; IntAct=EBI-475646, EBI-752324;
CC       P07196; P25815: S100P; NbExp=3; IntAct=EBI-475646, EBI-743700;
CC       P07196; P12757: SKIL; NbExp=6; IntAct=EBI-475646, EBI-2902468;
CC       P07196; Q8NB12: SMYD1; NbExp=3; IntAct=EBI-475646, EBI-8463848;
CC       P07196; Q13573: SNW1; NbExp=3; IntAct=EBI-475646, EBI-632715;
CC       P07196; Q99932-2: SPAG8; NbExp=3; IntAct=EBI-475646, EBI-11959123;
CC       P07196; Q9H7C4: SYNC; NbExp=3; IntAct=EBI-475646, EBI-11285923;
CC       P07196; Q9BQG1: SYT3; NbExp=3; IntAct=EBI-475646, EBI-17284568;
CC       P07196; Q86TJ2-3: TADA2B; NbExp=3; IntAct=EBI-475646, EBI-18173581;
CC       P07196; Q5VWN6: TASOR2; NbExp=3; IntAct=EBI-475646, EBI-745958;
CC       P07196; Q8TDR4: TCP10L; NbExp=3; IntAct=EBI-475646, EBI-3923210;
CC       P07196; Q13569: TDG; NbExp=3; IntAct=EBI-475646, EBI-348333;
CC       P07196; P54274: TERF1; NbExp=2; IntAct=EBI-475646, EBI-710997;
CC       P07196; Q5W5X9-3: TTC23; NbExp=3; IntAct=EBI-475646, EBI-9090990;
CC       P07196; Q9UGJ1-2: TUBGCP4; NbExp=3; IntAct=EBI-475646, EBI-10964469;
CC       P07196; Q5VYS8-5: TUT7; NbExp=3; IntAct=EBI-475646, EBI-9088812;
CC       P07196; O75604: USP2; NbExp=3; IntAct=EBI-475646, EBI-743272;
CC       P07196; P45880: VDAC2; NbExp=3; IntAct=EBI-475646, EBI-354022;
CC       P07196; P08670: VIM; NbExp=3; IntAct=EBI-475646, EBI-353844;
CC       P07196; P58304: VSX2; NbExp=3; IntAct=EBI-475646, EBI-6427899;
CC       P07196; Q53FD0-2: ZC2HC1C; NbExp=3; IntAct=EBI-475646, EBI-14104088;
CC       P07196; Q15776: ZKSCAN8; NbExp=3; IntAct=EBI-475646, EBI-2602314;
CC       P07196; Q9UJW8-4: ZNF180; NbExp=3; IntAct=EBI-475646, EBI-12055755;
CC       P07196; Q9NR11-2: ZNF302; NbExp=3; IntAct=EBI-475646, EBI-12988373;
CC       P07196; Q9C0F3: ZNF436; NbExp=3; IntAct=EBI-475646, EBI-8489702;
CC       P07196; Q96MN9-2: ZNF488; NbExp=3; IntAct=EBI-475646, EBI-25831733;
CC       P07196; Q68EA5: ZNF57; NbExp=3; IntAct=EBI-475646, EBI-8490788;
CC       P07196; Q7Z3I7: ZNF572; NbExp=3; IntAct=EBI-475646, EBI-10172590;
CC       P07196; Q96N77-2: ZNF641; NbExp=3; IntAct=EBI-475646, EBI-12939666;
CC       P07196; Q3KNS6-3: ZNF829; NbExp=3; IntAct=EBI-475646, EBI-18036029;
CC       P07196; O15535: ZSCAN9; NbExp=3; IntAct=EBI-475646, EBI-751531;
CC       P07196; Q86V28; NbExp=3; IntAct=EBI-475646, EBI-10259496;
CC       P07196; P14079: tax; Xeno; NbExp=4; IntAct=EBI-475646, EBI-9675698;
CC   -!- SUBCELLULAR LOCATION: Cell projection, axon
CC       {ECO:0000250|UniProtKB:P08551}. Cytoplasm, cytoskeleton
CC       {ECO:0000250|UniProtKB:P08551}.
CC   -!- DOMAIN: The extra mass and high charge density that distinguish the
CC       neurofilament proteins from all other intermediate filament proteins
CC       are due to the tailpiece extensions. This region may form a charged
CC       scaffolding structure suitable for interaction with other neuronal
CC       components or ions.
CC   -!- PTM: O-glycosylated. {ECO:0000250}.
CC   -!- PTM: Phosphorylated in the head and rod regions by the PKC kinase PKN1,
CC       leading to the inhibition of polymerization.
CC       {ECO:0000269|PubMed:8621664}.
CC   -!- PTM: Ubiquitinated in the presence of TRIM2 and UBE2D1. {ECO:0000250}.
CC   -!- DISEASE: Charcot-Marie-Tooth disease, demyelinating, 1F (CMT1F)
CC       [MIM:607734]: A dominant demyelinating form of Charcot-Marie-Tooth
CC       disease, a disorder of the peripheral nervous system, characterized by
CC       progressive weakness and atrophy, initially of the peroneal muscles and
CC       later of the distal muscles of the arms. Charcot-Marie-Tooth disease is
CC       classified in two main groups on the basis of electrophysiologic
CC       properties and histopathology: primary peripheral demyelinating
CC       neuropathies (designated CMT1 when they are dominantly inherited) and
CC       primary peripheral axonal neuropathies (CMT2). Demyelinating
CC       neuropathies are characterized by severely reduced nerve conduction
CC       velocities (less than 38 m/sec), segmental demyelination and
CC       remyelination with onion bulb formations on nerve biopsy, slowly
CC       progressive distal muscle atrophy and weakness, absent deep tendon
CC       reflexes, and hollow feet. CMT1F is characterized by onset in infancy
CC       or childhood (range 1 to 13 years). {ECO:0000269|PubMed:12566280,
CC       ECO:0000269|PubMed:15241803}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Charcot-Marie-Tooth disease, axonal, 2E (CMT2E) [MIM:607684]:
CC       A dominant axonal form of Charcot-Marie-Tooth disease, a disorder of
CC       the peripheral nervous system, characterized by progressive weakness
CC       and atrophy, initially of the peroneal muscles and later of the distal
CC       muscles of the arms. Charcot-Marie-Tooth disease is classified in two
CC       main groups on the basis of electrophysiologic properties and
CC       histopathology: primary peripheral demyelinating neuropathies
CC       (designated CMT1 when they are dominantly inherited) and primary
CC       peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group
CC       are characterized by signs of axonal degeneration in the absence of
CC       obvious myelin alterations, normal or slightly reduced nerve conduction
CC       velocities, and progressive distal muscle weakness and atrophy.
CC       {ECO:0000269|PubMed:10841809, ECO:0000269|PubMed:11220745,
CC       ECO:0000269|PubMed:12481988, ECO:0000269|PubMed:15241803,
CC       ECO:0000269|PubMed:17052987, ECO:0000269|PubMed:22206013,
CC       ECO:0000269|PubMed:25802885}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Charcot-Marie-Tooth disease, dominant intermediate G (CMTDIG)
CC       [MIM:617882]: An autosomal dominant, intermediate form of Charcot-
CC       Marie-Tooth disease, a disorder of the peripheral nervous system,
CC       characterized by progressive weakness and atrophy, initially of the
CC       peroneal muscles and later of the distal muscles of the arms. Dominant
CC       intermediate forms are characterized by clinical and pathologic
CC       features intermediate between demyelinating and axonal peripheral
CC       neuropathies, and motor median nerve conduction velocities ranging from
CC       25 to 45 m/sec. CMTDIG is phenotypically variable. Most affected
CC       individuals have onset in the first or second decades of slowly
CC       progressive distal motor weakness and atrophy, resulting in gait
CC       instability and distal upper limb impairment, as well as distal sensory
CC       impairment. {ECO:0000269|PubMed:14733962, ECO:0000269|PubMed:17052987,
CC       ECO:0000269|PubMed:25877835, ECO:0000269|PubMed:26645395}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: NF-L is the most abundant of the three neurofilament
CC       proteins and, like the other nonepithelial intermediate filament
CC       proteins, it can form homomeric 10-nm filaments.
CC   -!- SIMILARITY: Belongs to the intermediate filament family.
CC       {ECO:0000255|PROSITE-ProRule:PRU01188}.
CC   -!- WEB RESOURCE: Name=Inherited peripheral neuropathies mutation db;
CC       URL="https://uantwerpen.vib.be/CMTMutations";
CC   -!- WEB RESOURCE: Name=Human Intermediate Filament Mutation Database;
CC       URL="http://www.interfil.org";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X05608; CAA29097.1; -; Genomic_DNA.
DR   EMBL; AY156690; AAN74826.1; -; mRNA.
DR   EMBL; AC107373; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471080; EAW63598.1; -; Genomic_DNA.
DR   EMBL; CH471080; EAW63599.1; -; Genomic_DNA.
DR   EMBL; CH471080; EAW63600.1; -; Genomic_DNA.
DR   EMBL; BC039237; AAH39237.1; -; mRNA.
DR   EMBL; S70309; AAD14057.1; -; Genomic_DNA.
DR   CCDS; CCDS75712.1; -.
DR   PIR; S07144; S07144.
DR   RefSeq; NP_006149.2; NM_006158.4.
DR   AlphaFoldDB; P07196; -.
DR   SMR; P07196; -.
DR   BioGRID; 110822; 131.
DR   IntAct; P07196; 145.
DR   MINT; P07196; -.
DR   STRING; 9606.ENSP00000482169; -.
DR   GlyCosmos; P07196; 22 sites, 1 glycan.
DR   GlyGen; P07196; 24 sites, 1 O-linked glycan (21 sites).
DR   iPTMnet; P07196; -.
DR   PhosphoSitePlus; P07196; -.
DR   SwissPalm; P07196; -.
DR   BioMuta; NEFL; -.
DR   DMDM; 62511894; -.
DR   UCD-2DPAGE; P07196; -.
DR   EPD; P07196; -.
DR   jPOST; P07196; -.
DR   MassIVE; P07196; -.
DR   MaxQB; P07196; -.
DR   PeptideAtlas; P07196; -.
DR   ProteomicsDB; 51961; -.
DR   ABCD; P07196; 1 sequenced antibody.
DR   Antibodypedia; 73404; 1182 antibodies from 41 providers.
DR   DNASU; 4747; -.
DR   Ensembl; ENST00000610854.2; ENSP00000482169.2; ENSG00000277586.4.
DR   GeneID; 4747; -.
DR   KEGG; hsa:4747; -.
DR   MANE-Select; ENST00000610854.2; ENSP00000482169.2; NM_006158.5; NP_006149.2.
DR   UCSC; uc033bfe.2; human.
DR   AGR; HGNC:7739; -.
DR   CTD; 4747; -.
DR   DisGeNET; 4747; -.
DR   GeneCards; NEFL; -.
DR   GeneReviews; NEFL; -.
DR   HGNC; HGNC:7739; NEFL.
DR   HPA; ENSG00000277586; Tissue enriched (brain).
DR   MalaCards; NEFL; -.
DR   MIM; 162280; gene.
DR   MIM; 607684; phenotype.
DR   MIM; 607734; phenotype.
DR   MIM; 617882; phenotype.
DR   neXtProt; NX_P07196; -.
DR   OpenTargets; ENSG00000277586; -.
DR   Orphanet; 99939; Autosomal dominant Charcot-Marie-Tooth disease type 2E.
DR   Orphanet; 101085; Charcot-Marie-Tooth disease type 1F.
DR   Orphanet; 228374; Charcot-Marie-Tooth disease type 2B5.
DR   PharmGKB; PA31542; -.
DR   VEuPathDB; HostDB:ENSG00000277586; -.
DR   eggNOG; ENOG502QSXY; Eukaryota.
DR   GeneTree; ENSGT00940000156208; -.
DR   HOGENOM; CLU_012560_7_3_1; -.
DR   InParanoid; P07196; -.
DR   OMA; VYSQAMY; -.
DR   OrthoDB; 4640531at2759; -.
DR   PhylomeDB; P07196; -.
DR   PathwayCommons; P07196; -.
DR   Reactome; R-HSA-438066; Unblocking of NMDA receptors, glutamate binding and activation.
DR   Reactome; R-HSA-442982; Ras activation upon Ca2+ influx through NMDA receptor.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-9609736; Assembly and cell surface presentation of NMDA receptors.
DR   Reactome; R-HSA-9617324; Negative regulation of NMDA receptor-mediated neuronal transmission.
DR   Reactome; R-HSA-9620244; Long-term potentiation.
DR   SignaLink; P07196; -.
DR   SIGNOR; P07196; -.
DR   BioGRID-ORCS; 4747; 11 hits in 259 CRISPR screens.
DR   ChiTaRS; NEFL; human.
DR   GeneWiki; NEFL; -.
DR   GenomeRNAi; 4747; -.
DR   Pharos; P07196; Tbio.
DR   PRO; PR:P07196; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; P07196; protein.
DR   Bgee; ENSG00000277586; Expressed in dorsal root ganglion and 157 other tissues.
DR   Genevisible; P07196; HS.
DR   GO; GO:0030424; C:axon; IDA:UniProtKB.
DR   GO; GO:1904115; C:axon cytoplasm; IEA:GOC.
DR   GO; GO:0098981; C:cholinergic synapse; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; ISS:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030426; C:growth cone; IEA:Ensembl.
DR   GO; GO:0005882; C:intermediate filament; IBA:GO_Central.
DR   GO; GO:0005883; C:neurofilament; IDA:UniProtKB.
DR   GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl.
DR   GO; GO:0099160; C:postsynaptic intermediate filament cytoskeleton; IBA:GO_Central.
DR   GO; GO:0099182; C:presynaptic intermediate filament cytoskeleton; IEA:Ensembl.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:UniProtKB.
DR   GO; GO:0043274; F:phospholipase binding; IEA:Ensembl.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0030674; F:protein-macromolecule adaptor activity; ISS:BHF-UCL.
DR   GO; GO:0005200; F:structural constituent of cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0099184; F:structural constituent of postsynaptic intermediate filament cytoskeleton; IBA:GO_Central.
DR   GO; GO:0008089; P:anterograde axonal transport; IMP:UniProtKB.
DR   GO; GO:0019896; P:axonal transport of mitochondrion; IMP:UniProtKB.
DR   GO; GO:0007409; P:axonogenesis; IEA:Ensembl.
DR   GO; GO:0021987; P:cerebral cortex development; IEA:Ensembl.
DR   GO; GO:0021766; P:hippocampus development; IEA:Ensembl.
DR   GO; GO:0045109; P:intermediate filament organization; IMP:UniProtKB.
DR   GO; GO:0045105; P:intermediate filament polymerization or depolymerization; IEA:Ensembl.
DR   GO; GO:0040011; P:locomotion; IEA:Ensembl.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0097049; P:motor neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:2000672; P:negative regulation of motor neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0033693; P:neurofilament bundle assembly; IDA:UniProtKB.
DR   GO; GO:0060052; P:neurofilament cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; IEA:Ensembl.
DR   GO; GO:0014012; P:peripheral nervous system axon regeneration; IEA:Ensembl.
DR   GO; GO:0050772; P:positive regulation of axonogenesis; IEA:Ensembl.
DR   GO; GO:0099170; P:postsynaptic modulation of chemical synaptic transmission; IEA:Ensembl.
DR   GO; GO:0051258; P:protein polymerization; IEA:Ensembl.
DR   GO; GO:0031133; P:regulation of axon diameter; IEA:Ensembl.
DR   GO; GO:0090128; P:regulation of synapse maturation; IEA:Ensembl.
DR   GO; GO:1903937; P:response to acrylamide; IEA:Ensembl.
DR   GO; GO:0051412; P:response to corticosterone; IEA:Ensembl.
DR   GO; GO:0043434; P:response to peptide hormone; IEA:Ensembl.
DR   GO; GO:1903935; P:response to sodium arsenite; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0008090; P:retrograde axonal transport; IMP:UniProtKB.
DR   GO; GO:0021510; P:spinal cord development; IEA:Ensembl.
DR   Gene3D; 1.20.5.170; -; 1.
DR   Gene3D; 1.20.5.500; Single helix bin; 1.
DR   Gene3D; 1.20.5.1160; Vasodilator-stimulated phosphoprotein; 1.
DR   InterPro; IPR018039; IF_conserved.
DR   InterPro; IPR039008; IF_rod_dom.
DR   InterPro; IPR006821; Intermed_filament_DNA-bd.
DR   PANTHER; PTHR45652; GLIAL FIBRILLARY ACIDIC PROTEIN; 1.
DR   PANTHER; PTHR45652:SF8; NEUROFILAMENT LIGHT POLYPEPTIDE; 1.
DR   Pfam; PF00038; Filament; 1.
DR   Pfam; PF04732; Filament_head; 1.
DR   SMART; SM01391; Filament; 1.
DR   SUPFAM; SSF64593; Intermediate filament protein, coiled coil region; 2.
DR   PROSITE; PS00226; IF_ROD_1; 1.
DR   PROSITE; PS51842; IF_ROD_2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Cell projection; Charcot-Marie-Tooth disease; Coiled coil;
KW   Cytoplasm; Cytoskeleton; Direct protein sequencing; Disease variant;
KW   Glycoprotein; Intermediate filament; Methylation; Neurodegeneration;
KW   Neuropathy; Phosphoprotein; Reference proteome; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:22223895"
FT   CHAIN           2..543
FT                   /note="Neurofilament light polypeptide"
FT                   /id="PRO_0000063787"
FT   DOMAIN          90..400
FT                   /note="IF rod"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01188"
FT   REGION          2..92
FT                   /note="Head"
FT   REGION          93..124
FT                   /note="Coil 1A"
FT   REGION          125..137
FT                   /note="Linker 1"
FT   REGION          138..234
FT                   /note="Coil 1B"
FT   REGION          235..252
FT                   /note="Linker 12"
FT   REGION          253..271
FT                   /note="Coil 2A"
FT   REGION          272..280
FT                   /note="Linker 2"
FT   REGION          281..396
FT                   /note="Coil 2B"
FT   REGION          381..391
FT                   /note="Epitope; recognized by IF-specific monoclonal
FT                   antibody"
FT   REGION          397..543
FT                   /note="Tail"
FT   REGION          397..443
FT                   /note="Tail, subdomain A"
FT   REGION          444..543
FT                   /note="Tail, subdomain B (acidic)"
FT   REGION          462..543
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        470..522
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        523..543
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0007744|PubMed:22223895"
FT   MOD_RES         23
FT                   /note="Asymmetric dimethylarginine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P08551"
FT   MOD_RES         23
FT                   /note="Omega-N-methylarginine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P08551"
FT   MOD_RES         30
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P08551"
FT   MOD_RES         43
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P08551"
FT   MOD_RES         56
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P02548"
FT   MOD_RES         67
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P02548"
FT   MOD_RES         103
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P19527"
FT   MOD_RES         472
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P02548"
FT   MOD_RES         502
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P19527"
FT   MOD_RES         520
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P19527"
FT   CARBOHYD        21
FT                   /note="O-linked (GlcNAc) threonine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        27
FT                   /note="O-linked (GlcNAc) serine"
FT                   /evidence="ECO:0000250"
FT   VARIANT         7
FT                   /note="E -> K (in a Charcot-Marie-Tooth disease patient;
FT                   dbSNP:rs57848467)"
FT                   /evidence="ECO:0000269|PubMed:12566280"
FT                   /id="VAR_016017"
FT   VARIANT         8
FT                   /note="P -> L (in CMT1F; dbSNP:rs61491953)"
FT                   /evidence="ECO:0000269|PubMed:12566280"
FT                   /id="VAR_016018"
FT   VARIANT         8
FT                   /note="P -> Q (in CMT1F; dbSNP:rs61491953)"
FT                   /evidence="ECO:0000269|PubMed:12566280"
FT                   /id="VAR_016019"
FT   VARIANT         8
FT                   /note="P -> R (in CMT2E and CMT1F; dbSNP:rs61491953)"
FT                   /evidence="ECO:0000269|PubMed:11220745,
FT                   ECO:0000269|PubMed:12566280, ECO:0000269|PubMed:22206013"
FT                   /id="VAR_016020"
FT   VARIANT         22
FT                   /note="P -> S (in CMT2E; dbSNP:rs28928910)"
FT                   /evidence="ECO:0000269|PubMed:12481988,
FT                   ECO:0000269|PubMed:17052987, ECO:0000269|PubMed:22206013"
FT                   /id="VAR_016021"
FT   VARIANT         90
FT                   /note="E -> K (in CMT1F; dbSNP:rs58332872)"
FT                   /evidence="ECO:0000269|PubMed:12566280"
FT                   /id="VAR_016022"
FT   VARIANT         98
FT                   /note="N -> S (in CMT1F and CMTDIG; dbSNP:rs58982919)"
FT                   /evidence="ECO:0000269|PubMed:12566280,
FT                   ECO:0000269|PubMed:26645395"
FT                   /id="VAR_016023"
FT   VARIANT         213
FT                   /note="I -> M (in dbSNP:rs62636522)"
FT                   /evidence="ECO:0000269|PubMed:17052987"
FT                   /id="VAR_081565"
FT   VARIANT         265
FT                   /note="Y -> C (in CMT2E; unknown pathological significance;
FT                   dbSNP:rs587777880)"
FT                   /evidence="ECO:0000269|PubMed:25802885"
FT                   /id="VAR_081566"
FT   VARIANT         268
FT                   /note="L -> P (in CMT2E; dbSNP:rs62636502)"
FT                   /evidence="ECO:0000269|PubMed:17052987,
FT                   ECO:0000269|PubMed:25802885"
FT                   /id="VAR_081567"
FT   VARIANT         322..326
FT                   /note="Missing (in CMT2E; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:17052987"
FT                   /id="VAR_081568"
FT   VARIANT         332
FT                   /note="Q -> P (in CMT2E; dbSNP:rs59443585)"
FT                   /evidence="ECO:0000269|PubMed:10841809"
FT                   /id="VAR_009703"
FT   VARIANT         336
FT                   /note="L -> P (in CMT2E; unknown pathological significance;
FT                   dbSNP:rs587777881)"
FT                   /evidence="ECO:0000269|PubMed:15241803,
FT                   ECO:0000269|PubMed:25802885"
FT                   /id="VAR_021613"
FT   VARIANT         396
FT                   /note="E -> K (in CMTDIG and CMT2E; dbSNP:rs62636503)"
FT                   /evidence="ECO:0000269|PubMed:14733962,
FT                   ECO:0000269|PubMed:15241803, ECO:0000269|PubMed:17052987,
FT                   ECO:0000269|PubMed:22206013, ECO:0000269|PubMed:25877835"
FT                   /id="VAR_021614"
FT   VARIANT         440
FT                   /note="P -> L (in CMT2E; unknown pathological significance;
FT                   dbSNP:rs587777882)"
FT                   /evidence="ECO:0000269|PubMed:25802885"
FT                   /id="VAR_081569"
FT   VARIANT         468
FT                   /note="D -> N (in dbSNP:rs57153321)"
FT                   /evidence="ECO:0000269|PubMed:12566280,
FT                   ECO:0000269|PubMed:17052987"
FT                   /id="VAR_016024"
FT   VARIANT         527
FT                   /note="Missing (in CMT1F; dbSNP:rs3832558)"
FT                   /evidence="ECO:0000269|PubMed:12566280"
FT                   /id="VAR_016025"
FT   CONFLICT        28
FT                   /note="Missing (in Ref. 1; CAA29097)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        155
FT                   /note="N -> TN (in Ref. 1)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        161
FT                   /note="Q -> R (in Ref. 1; CAA29097)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        165
FT                   /note="E -> EE (in Ref. 1; CAA29097)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        195
FT                   /note="A -> R (in Ref. 1; CAA29097)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        452
FT                   /note="I -> T (in Ref. 1; CAA29097)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        461
FT                   /note="A -> S (in Ref. 1; CAA29097)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        472
FT                   /note="S -> D (in Ref. 8; AA sequence)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   543 AA;  61517 MW;  98C1712D8ACFF33A CRC64;
     MSSFSYEPYY STSYKRRYVE TPRVHISSVR SGYSTARSAY SSYSAPVSSS LSVRRSYSSS
     SGSLMPSLEN LDLSQVAAIS NDLKSIRTQE KAQLQDLNDR FASFIERVHE LEQQNKVLEA
     ELLVLRQKHS EPSRFRALYE QEIRDLRLAA EDATNEKQAL QGEREGLEET LRNLQARYEE
     EVLSREDAEG RLMEARKGAD EAALARAELE KRIDSLMDEI SFLKKVHEEE IAELQAQIQY
     AQISVEMDVT KPDLSAALKD IRAQYEKLAA KNMQNAEEWF KSRFTVLTES AAKNTDAVRA
     AKDEVSESRR LLKAKTLEIE ACRGMNEALE KQLQELEDKQ NADISAMQDT INKLENELRT
     TKSEMARYLK EYQDLLNVKM ALDIEIAAYR KLLEGEETRL SFTSVGSITS GYSQSSQVFG
     RSAYGGLQTS SYLMSTRSFP SYYTSHVQEE QIEVEETIEA AKAEEAKDEP PSEGEAEEEE
     KDKEEAEEEE AAEEEEAAKE ESEEAKEEEE GGEGEEGEET KEAEEEEKKV EGAGEEQAAK
     KKD
//
